A great start I feel. Germany is a tough market, demanding and exacting standards. Impressive sales there augur well for Stelfontas market penetration. There might be some resistance possibly from those who profit/ depend on surgical methods. Stelfontas circumvents this traditional method of treatment in many cases. Just my opinion, having read some vet news emphasising TT as an 'option'
